# US 2016/0354482 A1 · Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354482 A1
- Document ID: US20160354482A1
- Status: Published application
- Kind: A1
- Application number: 14/913,965
- Filed: 2014-08-26
- Published: 2016-12-08
- Earliest claimed: 2013-08-26
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Thomas NITTOLI; Nareshkumar F. JAIN; Thomas Patrick MARKOTAN
- Web page: https://patentgrep.com/patent/US20160354482A1

## CPC

- A61K 31/537: spiro-condensed or forming part of bridged ring systems
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 498/18: Bridged systems
- C07B 2200/07: Optical isomers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The disclosure relates to compositions comprising diastereomer of a macrolide exhibiting improved therapeutic profile in the context of inhibiting cell proliferation compared to the corresponding compositions comprising mixture of diastereomers. The disclosure further provides drug-ligand conjugates formed using diastereomer of the macrolide. The disclosure also provides novel method of preparation of diastereomer of the macrolide and their therapeutic uses.

## Claims

### Claim 1

A composition comprising a plurality of drug molecules of formula I:
wherein:
X is
Y is Y1 or Y2 further wherein
Y1 is
or H;
Y2 is —Cl, —Br, —I, or
Z is H or SO3H;
R1 and R2 are independently selected from H or alkyl;
n is an integer from 0 to 50;
and wherein the drug molecules present in the composition comprises a mixture of at least two diastereomers, a first diastereomer and a second diastereomer, further wherein said first diastereomer and second diastereomer are otherwise identical, except that said first and second diastereomers have different stereochemical configuration at a chiral carbon represented by (*) in formula X, wherein said chiral carbon atom is a carbon atom that is bound to a sulfur atom, and said first or second diastereomer is present in a diastereomeric excess of greater than 50%.

### Claim 2 (depends on 1)

The composition of claim 1, wherein n is 1, and R1 and R2 are each independently hydrogen.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the drug molecules are present in the composition in a diastereomeric excess of at least 95%.

### Claim 4 (depends on 1)

The composition of claim 1, wherein formula I is represented by:
or mixtures thereof in a diastereomeric excess of greater than 50%.

### Claim 5

A composition comprising a plurality of ligand-drug conjugates of Formula II:
wherein:
A is
W is selected from S, O, or NR3;
L is a ligand;
further wherein:
L is capable of binding to a cell or cell population;
R1, R2 and R3 are each independently selected from H or alkyl;
n is an integer from 0 to 10;
p is an integer from 1 to 10;
and wherein the ligand-drug conjugates are present in the composition in a diastereomeric excess of greater than 50%.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the ligand is an antibody or an antigen-binding fragment thereof, W is NH, and R1, R2 are each independently selected from H.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the antibody or antigen-binding fragment thereof specifically binds a tumor-associated antigen.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the ligand-drug conjugates are present in the composition in a diastereomeric excess of more than 95%.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the tumor-associated antigen is selected from the group consisting of AFP, ALK, BAGE proteins, β-catenin, brc-abl, BRCA1, BORIS, CA9, carbonic anhydrase IX, caspase-8, CD40, CDK4, CEA, CTLA4, CLEC12A, cyclin-B1, CYP1B1, EGFR, EGFRvIII, ErbB2/Her2, ErbB3, ErbB4, ETV6-AML, EphA2, Fra-1, FOLR1, GAGE proteins (e.g., GAGE-1, -2), GD2, GD3, GloboH, glypican-3, GM3, gp100, Her2, HLA/B-raf, HLA/k-ras, HLA/MAGE-A3, hTERT, LMP2, MAGE proteins (e.g., MAGE-1, -2, -3, -4, -6, and -12), MART-1, mesothelin, ML-IAP, Muc1, Muc16 (CA-125), MUM1, NA17, NY-BR1, NY-BR62, NY-BR85, NY-ESO1, OX40, p15, p53, PAP, PAX3, PAX5, PCTA-1, PLAC1, PRLR, PRAME, PSMA (FOLH1), RAGE proteins, Ras, RGS5, Rho, SART-1, SART-3, Steap-1, Steap-2, survivin, TAG-72, TGF-β, TMPRSS2, Tn, TRP-1, TRP-2, tyrosinase, and uroplakin-3.

### Claim 10

A method for preparing composition comprising a plurality of drug molecules of formula I:
wherein:
X is
Y is Y1 or Y2 further wherein
Y1 is
or H;
Y2 is —Cl, —Br, —I, or
R1 and R2 are independently selected from H or alkyl;
n is an integer from 0 to 50;
and wherein the drug molecules present in the composition comprises a mixture of at least two diastereomers, a first diastereomer and a second diastereomer, further wherein said first diastereomer and second diastereomer are otherwise identical, except that said first and second diastereomers have different stereochemical configuration at a chiral carbon represented by (*) in formula X, wherein said chiral carbon atom is a carbon atom that is bound to a sulfur atom, and said first or second diastereomer is present in a diastereomeric excess of greater than 50%,
the method comprising:
(a) providing a mixture comprising
(i) a starting material which has a formula III:
(ii) a compound of formula IV:
Y1 is
or H;
Y2 is —Cl, —Br, —I, or
Z is H or SO3H;
R1 and R2 are independently selected from H or alkyl; and
each n is an integer from 0 to 50;
(iii) an organic solvent,
(iv) water, and
(v) a solid substrate;
(b) allowing the mixture of step (a) to react until some of the starting material is converted to the compound of formula I; and
(c) removing crude compound of formula I from the mixture of step (b).

### Claim 11 (depends on 10)

The method of claim 10, further comprising (d) purifying the compound of formula I obtained in step (c).

### Claim 12 (depends on 10)

The method of claim 10, wherein the solid substrate is selected from the group consisting of silica gel, celite, alumina, a zeolite, and crushed molecular sieves.

### Claim 13 (depends on 10)

The method of claim 10, wherein n is 1, and R1 and R2 are each independently hydrogen.

### Claim 14 (depends on 10)

The method of claim 10, wherein the organic solvent comprises a polar aprotic solvent.

### Claim 15 (depends on 14)

The method of claim 14, wherein the polar aprotic solvent comprises acetonitrile.

### Claim 16 (depends on 10)

The method of claim 10, wherein the organic solvent and the water are present in ratio from about 1:1 to about 4:1 or from about 1:1 to about 10:1.

### Claim 17 (depends on 10)

The method of claim 10, wherein the molar ratio of the starting material having formula III and the compound of formula IV is from about 1:1 to about 1:3.

### Claim 18 (depends on 10)

The method of claim 10, further comprising combining the compound of formula I with an antibody or antigen-binding fragment thereof to make an antibody-drug conjugate.

### Claim 19 (depends on 18)

The method of claim 18, wherein the compound of formula I is attached to the antibody or antigen-binding fragment via an S, O, or NR3.

### Claim 20 (depends on 10)

The method of claim 10, wherein the formula I is represented by the following structure:
in a diastereomeric excess of greater than 50%.

### Claim 21 (depends on 1, 5)

The composition of claim 1 or 5, wherein the drug molecules or the ligand-drug conjugates are contained within the composition in a therapeutically effective amount, and further comprising a pharmaceutically acceptable diluent, carrier or excipient.

### Claim 22 (depends on 21)

The composition of claim 21, further comprising a therapeutically effective amount of a second chemotherapeutic agent.

### Claim 23 (depends on 1, 5)

A method of treating a disease sensitive to treatment with said method, said method comprising parenterally administering to a patient in need thereof a therapeutically effective dose of the composition of claim 1 or 5.

### Claim 24 (depends on 23)

The method of claim 23, wherein said disease is selected from tumor, autoimmune disease, and inflammatory disease.

### Claim 25

A composition comprising a plurality of drug molecules of formula I:
wherein:
X is
Y is
or H;
R1 and R2 are each independently selected from H or alkyl;
n is an integer from 0 to 10; and
wherein the drug molecules are present in the composition in an diastereomeric excess of greater than 50% and show greater anti-proliferative activity than a corresponding composition comprising drug molecules of formula I that are not present in a diastereomeric excess of greater than 50%.

### Claim 26 (depends on 1)

The composition of claim 1, wherein one of the at least two diastereomers is a compound of formula (i)

### Claim 27 (depends on 1)

The composition of claim 1, wherein one of the at least two diastereomers is a compound of formula (ii)

### Claim 28 (depends on 1)

The composition of claim 1, wherein one of the at least two diastereomers is characterized by a 1H NMR spectra of FIG. 1.

### Claim 29

A compound of formula (i):
wherein the compound is stereomerically pure.

### Claim 30

A compound of formula (ii):
wherein the compound is stereomerically pure.
